Cal-Maine family shareholders cashed out after egg price surge and antitrust scrutiny

Traders Union
All News
Financial News
Cal-Maine shareholders sell after egg surge

Highlights

Descendants of Cal-Maine founder Fred R Adams Jr sell nearly 3 million converted shares for $92.75 each in April 2025, reaping about $320 million, relinquishing majority control but retaining significant holdings.
Cal-Maine faces a U.S. Department of Justice-led antitrust lawsuit alleging manipulation of Urner Barry benchmark egg prices, agreeing to donate 53 million eggs and pay $3.3 million in settlements without admitting liability.
Fiscal 2025 net sales surge to $4.3 billion from $2.3 billion year-on-year, net income rises to $1.2 billion from $277.9 million, and shares double to $95 amid extreme egg price volatility.

Stake sale follows share conversion and buyback

As reported by Financial Times, descendants of Cal-Maine founder Fred R Adams Jr reap about $320 million from a secondary stock sale in April 2025 after converting super-voting shares into common stock and giving up majority control of the company.

The Adams family had controlled Cal-Maine through class A shares held by Daughters LLC. In February 2025, Cal-Maine says the four daughters of the late founder and board chair Adolphus "Dolph" Baker agree to convert those shares into ordinary stock, a step the company says would allow family members to consider diversifying their personal portfolios.

Goldman Sachs leads the April 2025 offering, which includes nearly 3 million shares sold at $92.75 each. Cal-Maine does not sell any shares in the offering and receives no proceeds, but it separately agrees to repurchase 551,876 shares from the selling family members for about $50 million under a new $500 million buyback programme, with both transactions closing on April 17.

The sale is not a full exit. Family members retain shares after the transaction, and Baker remains chair of the board.

Cal-Maine first discloses in an April 8, 2025 quarterly filing that it receives a civil investigative demand from the U.S. Department of Justice in March tied to a widely publicized antitrust investigation into nationwide increases in egg prices. The family agreement is announced before that demand is received or disclosed, but the share conversion, offering and company buyback all take place afterward.

Benchmark case adds pressure on egg industry

A complaint filed last month by the U.S. Department of Justice and 17 state attorneys-general alleges executives at Cal-Maine, Hickman's Egg Ranch and Versova work to inflate pricing quotations to Urner Barry, a benchmark service used to price billions of eggs sold to supermarkets, restaurants and food-service companies each year.

Prosecutors say that after calls on December 4, 2024 with executives from Cal-Maine and Versova, Hickman's chief executive receives a text from what the complaint describes as Cal-Maine's former chief executive saying, "Let it rip." Authorities allege the companies then post more offers to buy eggs, including a greater share at premium prices and left unfilled, to signal stronger demand and lift benchmark quotations.

Cal-Maine denies wrongdoing and says its conduct is lawful. The proposed settlement, announced last week, does not include an admission of liability and still requires court approval; under its terms, Cal-Maine, Versova and Hickman's agree to donate 53 million eggs to food banks and non-profit groups and make $3.3 million in payments to participating states, while also ending competitor communications aimed at affecting benchmark publications.

The scrutiny comes after extraordinary earnings growth at Cal-Maine. Net sales rise to $4.3 billion in fiscal 2025 from $2.3 billion a year earlier, net income climbs to $1.2 billion from $277.9 million, and gross profit reaches $1.85 billion from $541.6 million, driven mainly by higher average selling prices and volumes.

Egg prices themselves swing sharply during the period. Large grade A eggs climb to more than $8.50 a dozen in February 2025, according to Expana, before falling back to about $2.19 in May this year; Cal-Maine stock also roughly doubles from about $45 in June 2022 to $95 in March 2025. The company continues to say high prices reflect avian flu, tight supply, strong demand, the Covid-19 pandemic, weather, inflation and other market dynamics.

Aviva’s £350 million share buyback and the stock’s technical setup were the focus of our earlier coverage, highlighting how price action weakened despite supportive capital returns and strong profit growth. We noted mixed signals: Aviva remained above key moving averages, but overbought indicators and lingering selling pressure made near-term volatility around key support/resistance levels a central risk to watch.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.